Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

The role of heparan sulfate maturation in cancer: a focus on the 3O-sulfation and the enigmatic 3O-sulfotransferases (HS3STs).

Gulberti S, Mao X, Bui C, Fournel-Gigleux S.

Semin Cancer Biol. 2019 Nov 8. pii: S1044-579X(19)30266-4. doi: 10.1016/j.semcancer.2019.10.009. [Epub ahead of print] Review.

PMID:
31711992
2.

Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers-Danlos syndrome.

Van Damme T, Pang X, Guillemyn B, Gulberti S, Syx D, De Rycke R, Kaye O, de Die-Smulders CEM, Pfundt R, Kariminejad A, Nampoothiri S, Pierquin G, Bulk S, Larson AA, Chatfield KC, Simon M, Legrand A, Gerard M, Symoens S, Fournel-Gigleux S, Malfait F.

Hum Mol Genet. 2018 Oct 15;27(20):3475-3487. doi: 10.1093/hmg/ddy234.

PMID:
29931299
3.

Synthesis of a library of variously modified 4-methylumbelliferyl xylosides and a structure-activity study of human β4GalT7.

Dahbi S, Jacquinet JC, Bertin-Jung I, Robert A, Ramalanjaona N, Gulberti S, Fournel-Gigleux S, Lopin-Bon C.

Org Biomol Chem. 2017 Nov 22;15(45):9653-9669. doi: 10.1039/c7ob02530k.

PMID:
29116283
4.

The 2017 international classification of the Ehlers-Danlos syndromes.

Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, Bloom L, Bowen JM, Brady AF, Burrows NP, Castori M, Cohen H, Colombi M, Demirdas S, De Backer J, De Paepe A, Fournel-Gigleux S, Frank M, Ghali N, Giunta C, Grahame R, Hakim A, Jeunemaitre X, Johnson D, Juul-Kristensen B, Kapferer-Seebacher I, Kazkaz H, Kosho T, Lavallee ME, Levy H, Mendoza-Londono R, Pepin M, Pope FM, Reinstein E, Robert L, Rohrbach M, Sanders L, Sobey GJ, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Wheeldon N, Zschocke J, Tinkle B.

Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):8-26. doi: 10.1002/ajmg.c.31552.

PMID:
28306229
5.

The Ehlers-Danlos syndromes, rare types.

Brady AF, Demirdas S, Fournel-Gigleux S, Ghali N, Giunta C, Kapferer-Seebacher I, Kosho T, Mendoza-Londono R, Pope MF, Rohrbach M, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Zschocke J, Malfait F.

Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):70-115. doi: 10.1002/ajmg.c.31550. Review.

PMID:
28306225
6.

'Click'-xylosides as initiators of the biosynthesis of glycosaminoglycans: Comparison of mono-xylosides with xylobiosides.

Chatron-Colliet A, Brusa C, Bertin-Jung I, Gulberti S, Ramalanjaona N, Fournel-Gigleux S, Brézillon S, Muzard M, Plantier-Royon R, Rémond C, Wegrowski Y.

Chem Biol Drug Des. 2017 Mar;89(3):319-326. doi: 10.1111/cbdd.12865. Epub 2016 Nov 2.

PMID:
27618481
7.

The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer.

Mao X, Gauche C, Coughtrie MW, Bui C, Gulberti S, Merhi-Soussi F, Ramalanjaona N, Bertin-Jung I, Diot A, Dumas D, De Freitas Caires N, Thompson AM, Bourdon JC, Ouzzine M, Fournel-Gigleux S.

Oncogene. 2016 Sep 22;35(38):5043-55. doi: 10.1038/onc.2016.44. Epub 2016 Apr 4.

PMID:
27041583
8.

Targeting of Proteoglycan Synthesis Pathway: A New Strategy to Counteract Excessive Matrix Proteoglycan Deposition and Transforming Growth Factor-β1-Induced Fibrotic Phenotype in Lung Fibroblasts.

Shaukat I, Barré L, Venkatesan N, Li D, Jaquinet JC, Fournel-Gigleux S, Ouzzine M.

PLoS One. 2016 Jan 11;11(1):e0146499. doi: 10.1371/journal.pone.0146499. eCollection 2016.

9.

Probing the acceptor active site organization of the human recombinant β1,4-galactosyltransferase 7 and design of xyloside-based inhibitors.

Saliba M, Ramalanjaona N, Gulberti S, Bertin-Jung I, Thomas A, Dahbi S, Lopin-Bon C, Jacquinet JC, Breton C, Ouzzine M, Fournel-Gigleux S.

J Biol Chem. 2015 Mar 20;290(12):7658-70. doi: 10.1074/jbc.M114.628123. Epub 2015 Jan 7.

10.

The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication.

Ouzzine M, Gulberti S, Ramalanjaona N, Magdalou J, Fournel-Gigleux S.

Front Cell Neurosci. 2014 Oct 28;8:349. doi: 10.3389/fncel.2014.00349. eCollection 2014. Review.

11.

CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics.

Siest G, Fournel-Gigleux S, Magdalou J.

Drug Metabol Drug Interact. 2014;29(4):207-9. doi: 10.1515/dmdi-2014-0030. No abstract available.

PMID:
25367614
12.

Defective initiation of glycosaminoglycan synthesis due to B3GALT6 mutations causes a pleiotropic Ehlers-Danlos-syndrome-like connective tissue disorder.

Malfait F, Kariminejad A, Van Damme T, Gauche C, Syx D, Merhi-Soussi F, Gulberti S, Symoens S, Vanhauwaert S, Willaert A, Bozorgmehr B, Kariminejad MH, Ebrahimiadib N, Hausser I, Huysseune A, Fournel-Gigleux S, De Paepe A.

Am J Hum Genet. 2013 Jun 6;92(6):935-45. doi: 10.1016/j.ajhg.2013.04.016. Epub 2013 May 9.

13.

Regulation of xylosyltransferase I gene expression by interleukin 1β in human primary chondrocyte cells: mechanism and impact on proteoglycan synthesis.

Khair M, Bourhim M, Barré L, Li D, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M.

J Biol Chem. 2013 Jan 18;288(3):1774-84. doi: 10.1074/jbc.M112.419887. Epub 2012 Dec 5.

14.

Recent structures, evolution and mechanisms of glycosyltransferases.

Breton C, Fournel-Gigleux S, Palcic MM.

Curr Opin Struct Biol. 2012 Oct;22(5):540-9. doi: 10.1016/j.sbi.2012.06.007. Epub 2012 Jul 19. Review.

PMID:
22819665
15.

Xylosyltransferase-I regulates glycosaminoglycan synthesis during the pathogenic process of human osteoarthritis.

Venkatesan N, Barré L, Bourhim M, Magdalou J, Mainard D, Netter P, Fournel-Gigleux S, Ouzzine M.

PLoS One. 2012;7(3):e34020. doi: 10.1371/journal.pone.0034020. Epub 2012 Mar 30.

16.

Proteoglycans and cartilage repair.

Ouzzine M, Venkatesan N, Fournel-Gigleux S.

Methods Mol Biol. 2012;836:339-55. doi: 10.1007/978-1-61779-498-8_22.

PMID:
22252645
17.

Chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT-1) involved in chondroitin sulfate initiation: Impact of sulfation on activity and specificity.

Gulberti S, Jacquinet JC, Chabel M, Ramalanjaona N, Magdalou J, Netter P, Coughtrie MW, Ouzzine M, Fournel-Gigleux S.

Glycobiology. 2012 Apr;22(4):561-71. doi: 10.1093/glycob/cwr172. Epub 2011 Dec 7.

PMID:
22156920
18.

Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum.

Tucker TG, Milne AM, Fournel-Gigleux S, Fenner KS, Coughtrie MW.

Biochem Pharmacol. 2012 Jan 15;83(2):279-85. doi: 10.1016/j.bcp.2011.10.017. Epub 2011 Oct 31.

PMID:
22062654
19.

Identification of key functional residues in the active site of human {beta}1,4-galactosyltransferase 7: a major enzyme in the glycosaminoglycan synthesis pathway.

Talhaoui I, Bui C, Oriol R, Mulliert G, Gulberti S, Netter P, Coughtrie MW, Ouzzine M, Fournel-Gigleux S.

J Biol Chem. 2010 Nov 26;285(48):37342-58. doi: 10.1074/jbc.M110.151951. Epub 2010 Sep 14.

20.

Molecular characterization of β1,4-galactosyltransferase 7 genetic mutations linked to the progeroid form of Ehlers-Danlos syndrome (EDS).

Bui C, Talhaoui I, Chabel M, Mulliert G, Coughtrie MW, Ouzzine M, Fournel-Gigleux S.

FEBS Lett. 2010 Sep 24;584(18):3962-8. doi: 10.1016/j.febslet.2010.08.001. Epub 2010 Aug 6.

21.

The use of hepatocytes to investigate UDP-glucuronosyltransferases and sulfotransferases.

Fournel-Gigleux S, Coughtrie MW, Ouzzine M, Magdalou J.

Methods Mol Biol. 2010;640:309-26. doi: 10.1007/978-1-60761-688-7_17.

PMID:
20645060
22.

Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells.

Bui C, Ouzzine M, Talhaoui I, Sharp S, Prydz K, Coughtrie MW, Fournel-Gigleux S.

FASEB J. 2010 Feb;24(2):436-50. doi: 10.1096/fj.09-136291. Epub 2009 Oct 7.

PMID:
19812376
23.

Insights on membrane topology and structure/function of UDP-glucuronosyltransferases.

Magdalou J, Fournel-Gigleux S, Ouzzine M.

Drug Metab Rev. 2010 Feb;42(1):159-66. doi: 10.3109/03602530903209270. Review.

PMID:
19807219
24.

[Agrecan and articular cartilage: assessment of glycosyltransferases for the restoration of cartilage matrix in osteoarthritis].

Magdalou J, Netter P, Fournel-Gigleux S, Ouzzine M.

J Soc Biol. 2008;202(4):281-8. doi: 10.1051/jbio:2008029. Epub 2008 Dec 19. French.

PMID:
19094927
25.

Modulation of xylosyltransferase I expression provides a mechanism regulating glycosaminoglycan chain synthesis during cartilage destruction and repair.

Venkatesan N, Barré L, Magdalou J, Mainard D, Netter P, Fournel-Gigleux S, Ouzzine M.

FASEB J. 2009 Mar;23(3):813-22. doi: 10.1096/fj.08-118166. Epub 2008 Nov 10.

PMID:
19001053
26.

Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A.

Li D, Fournel-Gigleux S, Barré L, Mulliert G, Netter P, Magdalou J, Ouzzine M.

J Biol Chem. 2007 Dec 14;282(50):36514-24. Epub 2007 Oct 23.

27.

Molecular basis for acceptor substrate specificity of the human beta1,3-glucuronosyltransferases GlcAT-I and GlcAT-P involved in glycosaminoglycan and HNK-1 carbohydrate epitope biosynthesis, respectively.

Fondeur-Gelinotte M, Lattard V, Gulberti S, Oriol R, Mulliert G, Coughtrie MW, Magdalou J, Netter P, Ouzzine M, Fournel-Gigleux S.

Glycobiology. 2007 Aug;17(8):857-67. Epub 2007 Jun 13.

PMID:
17567734
28.

[Chondrocyte glycosyltransferases: new pharmacological targets for degenerative diseases of articular cartilage?].

Magdalou J, Ouzzine M, Netter P, Fournel-Gigleux S.

Bull Acad Natl Med. 2006 Oct;190(7):1385-97; discussion 1397-8, 1475-7. French.

PMID:
17450675
29.

Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33.

Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, Ouzzine M.

FEBS J. 2007 Mar;274(5):1256-64. Epub 2007 Jan 29.

30.

Phylogenetic and mutational analyses reveal key residues for UDP-glucuronic acid binding and activity of beta1,3-glucuronosyltransferase I (GlcAT-I).

Fondeur-Gelinotte M, Lattard V, Oriol R, Mollicone R, Jacquinet JC, Mulliert G, Gulberti S, Netter P, Magdalou J, Ouzzine M, Fournel-Gigleux S.

Protein Sci. 2006 Jul;15(7):1667-78.

31.

Evidence of calcium-dependent pathway in the regulation of human beta1,3-glucuronosyltransferase-1 (GlcAT-I) gene expression: a key enzyme in proteoglycan synthesis.

Barré L, Venkatesan N, Magdalou J, Netter P, Fournel-Gigleux S, Ouzzine M.

FASEB J. 2006 Aug;20(10):1692-4. Epub 2006 Jun 28.

PMID:
16807373
32.

Role of the carboxyl terminal stop transfer sequence of UGT1A6 membrane protein in ER targeting and translocation of upstream lumenal domain.

Ouzzine M, Barré L, Netter P, Magdalou J, Fournel-Gigleux S.

FEBS Lett. 2006 Apr 3;580(8):1953-8. Epub 2006 Mar 3.

33.

Structure of UDP-glucuronosyltransferases in membranes.

Radominska-Pandya A, Ouzzine M, Fournel-Gigleux S, Magdalou J.

Methods Enzymol. 2005;400:116-47. Review.

PMID:
16399347
34.

Purification and characterization of a soluble form of the recombinant human galactose-beta1,3-glucuronosyltransferase I expressed in the yeast Pichia pastoris.

Lattard V, Fondeur-Gelinotte M, Gulberti S, Jacquinet JC, Boudrant J, Netter P, Magdalou J, Ouzzine M, Fournel-Gigleux S.

Protein Expr Purif. 2006 May;47(1):137-43. Epub 2005 Nov 4.

PMID:
16300963
35.

Modifications of the glycosaminoglycan-linkage region of proteoglycans: phosphorylation and sulfation determine the activity of the human beta1,4-galactosyltransferase 7 and beta1,3-glucuronosyltransferase I.

Gulberti S, Lattard V, Fondeur M, Jacquinet JC, Mulliert G, Netter P, Magdalou J, Ouzzine M, Fournel-Gigleux S.

ScientificWorldJournal. 2005 Jul 12;5:510-4. Review. No abstract available.

36.

[Stimulation of proteoglycan synthesis towards cartilage repair].

Venkatesan N, Magdalou J, Netter P, Fournel-Gigleux S, Ouzzine M.

Med Sci (Paris). 2005 May;21(5):471-3. French. No abstract available.

38.

Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair.

Venkatesan N, Barré L, Benani A, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M.

Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18087-92. Epub 2004 Dec 15.

40.

Assessment of catechol induction and glucuronidation in rat liver microsomes.

Elovaara E, Mikkola J, Luukkanen L, Antonio L, Fournel-Gigleux S, Burchell B, Magdalou J, Taskinen J.

Drug Metab Dispos. 2004 Dec;32(12):1426-33. Epub 2004 Sep 15.

PMID:
15371300
41.

The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation.

Ouzzine M, Barré L, Netter P, Magdalou J, Fournel-Gigleux S.

Drug Metab Rev. 2003 Nov;35(4):287-303. Review. No abstract available.

PMID:
14705862
42.

The functional glycosyltransferase signature sequence of the human beta 1,3-glucuronosyltransferase is a XDD motif.

Gulberti S, Fournel-Gigleux S, Mulliert G, Aubry A, Netter P, Magdalou J, Ouzzine M.

J Biol Chem. 2003 Aug 22;278(34):32219-26. Epub 2003 Jun 6.

43.

The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6.

Senay C, Jedlitschky G, Terrier N, Burchell B, Magdalou J, Fournel-Gigleux S.

Biochim Biophys Acta. 2002 May 20;1597(1):90-6.

PMID:
12009407
44.

The donor substrate specificity of the human beta 1,3-glucuronosyltransferase I toward UDP-glucuronic acid is determined by two crucial histidine and arginine residues.

Ouzzine M, Gulberti S, Levoin N, Netter P, Magdalou J, Fournel-Gigleux S.

J Biol Chem. 2002 Jul 12;277(28):25439-45. Epub 2002 May 1.

45.

Characterization of catechol glucuronidation in rat liver.

Antonio L, Grillasca JP, Taskinen J, Elovaara E, Burchell B, Piet MH, Ethell B, Ouzzine M, Fournel-Gigleux S, Magdalou J.

Drug Metab Dispos. 2002 Feb;30(2):199-207.

PMID:
11792691
46.
47.

Importance of histidine residues for the function of the human liver UDP-glucuronosyltransferase UGT1A6: evidence for the catalytic role of histidine 370.

Ouzzine M, Antonio L, Burchell B, Netter P, Fournel-Gigleux S, Magdalou J.

Mol Pharmacol. 2000 Dec;58(6):1609-15.

PMID:
11093802
48.

Structure/function of the human Ga1beta1,3-glucuronosyltransferase. Dimerization and functional activity are mediated by two crucial cysteine residues.

Ouzzine M, Gulberti S, Netter P, Magdalou J, Fournel-Gigleux S.

J Biol Chem. 2000 Sep 8;275(36):28254-60.

49.
50.

In vitro stereoselective degradation of carprofen glucuronide by human serum albumin. Characterization of sites and reactive amino acids.

Georges H, Presle N, Buronfosse T, Fournel-Gigleux S, Netter P, Magdalou J, Lapicque F.

Chirality. 2000 Feb;12(2):53-62.

PMID:
10637410

Supplemental Content

Loading ...
Support Center